All In Biotech

Drug Trial Radar · NCT06237426

An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD

A 52-Week, Open-Label Evaluation of the Long-term Efficacy and Safety of Single and Repeated Treatments With Methylone for the Treatment of PTSD IMPACT-EXT (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

44

Actual

Start

Mar 6, 2024

Primary completion

Oct 6, 2025

Study completion Oct 6, 2025

Sponsor

Lead sponsor
Transcend TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 71 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an extension study of participants who previously completed a Transcend-sponsored clinical trial evaluating TSND-201 as a treatment for PTSD. Participants will be followed for up to 52 weeks. During the 52 week period, PTSD symptoms and safety will be assessed monthly. Participants' PTSD symptoms will be assessed at each observational visit and if criteria for Relapse has been met, participants may be eligible to receive a course of TSND-201 treatment.

Conditions

  • Post Traumatic Stress Disorder

Interventions

  • MethyloneDrug

    A course of treatment includes 4 weekly doses of TSND-201.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From IMPACT-1 Baseline in Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity ScoreTime frame: Week 10 and Week 16

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Mountain View Clinical Research

    Denver, Colorado

  • Sunstone Medical

    Rockville, Maryland

  • Cedar Clinical Research, Inc

    Draper, Utah

  • La Nua Mental Health Centre

    Galway, Ireland

  • Clerkenwell Health

    London, United Kingdom

  • Kings College

    London, United Kingdom

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, England, United Kingdom

  • Mirabilis Health

    Belfast, Northern Ireland, United Kingdom

  • NHS Greater Glasgow and Clyde

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.